LEXICON PHARMACEUTICALS, INC. (LXRX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 10M 20M 30M Q3 '21: 23K Q4 '21: 14K Q1 '22: 37K Q2 '22: 35K Q3 '22: 39K Q4 '22: 28K Q1 '23: 24K Q2 '23: 317K Q3 '23: 162K Q4 '23: 702K Q1 '24: 1.1M Q2 '24: 1.6M Q3 '24: 1.8M Q4 '24: 26.6M Q1 '25: 1.3M Q2 '25: 28.9M Q3 '25: 14.2M Q4 '25: 5.5M Q1 '26: 21.1M Q2 '26: 692K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

0 10M 20M 30M Q3 '21: 23K Q4 '21: 14K Q1 '22: 37K Q2 '22: 35K Q3 '22: 39K Q4 '22: 28K Q1 '23: 24K Q2 '23: 309K Q3 '23: 155K Q4 '23: 632K Q1 '24: 1.1M Q2 '24: 1.5M Q3 '24: 1.7M Q4 '24: 26.2M Q1 '25: 1.2M Q2 '25: 28.8M Q3 '25: 14.2M Q4 '25: 5.3M Q1 '26: 21M Q2 '26: 653K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -23M Q4 '21: -25.3M Q1 '22: -23.4M Q2 '22: -24M Q3 '22: -23.1M Q4 '22: -30.3M Q1 '23: -31.1M Q2 '23: -44.2M Q3 '23: -49.6M Q4 '23: -46.7M Q1 '24: -45.3M Q2 '24: -55.4M Q3 '24: -63.7M Q4 '24: -32.7M Q1 '25: -25.7M Q2 '25: 3.7M Q3 '25: -12.2M Q4 '25: -14.8M Q1 '26: -996K Q2 '26: -26.5M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-75M -50M -25M 0 25M 50M 75M Q3 '21: -23.1M Q4 '21: -25.6M Q1 '22: -23.5M Q2 '22: -24.6M Q3 '22: -23.4M Q4 '22: -30.5M Q1 '23: -31.9M Q2 '23: -44.9M Q3 '23: -50.5M Q4 '23: -49.8M Q1 '24: -48.4M Q2 '24: -53.4M Q3 '24: -64.8M Q4 '24: -33.8M Q1 '25: -25.3M Q2 '25: 3.3M Q3 '25: -12.8M Q4 '25: -15.5M Q1 '26: -1M Q2 '26: -31.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 150K 300K 450K Q3 '21: 0 Q4 '21: 0 Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 8K Q3 '23: 7K Q4 '23: 70K Q1 '24: 31K Q2 '24: 166K Q3 '24: 71K Q4 '24: 348K Q1 '25: 30K Q2 '25: 33K Q3 '25: 10K Q4 '25: 201K Q1 '26: 108K Q2 '26: 39K Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '21: -17.1M Q4 '21: -22.8M Q1 '22: -23.4M Q2 '22: -24.4M Q3 '22: -19.4M Q4 '22: -21.6M Q1 '23: -31.6M Q2 '23: -38.1M Q3 '23: -41.6M Q4 '23: -50.5M Q1 '24: -55.1M Q2 '24: -48.5M Q3 '24: -53.6M Q4 '24: -21.5M Q1 '25: -43.8M Q2 '25: 17M Q3 '25: -23.8M Q4 '25: -17.2M Q1 '26: -14.7M Q2 '26: -9.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-60M -40M -20M 0 20M 40M 60M Q3 '20: -40.4M Q4 '20: -34.3M Q1 '21: -25.2M Q2 '21: -22.8M Q3 '21: -17.4M Q4 '21: -22.9M Q1 '22: -23.5M Q2 '22: -24.4M Q3 '22: -19.4M Q4 '22: -22.8M Q1 '23: -31.9M Q2 '23: -38.3M Q3 '23: -41.7M Q4 '23: -50.5M Q1 '24: -55.1M Q2 '24: -48.8M Q3 '24: -53.9M Q4 '24: -22M Q3 '25: -23.8M Q4 '25: -17.2M Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q4 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 150M 300M 450M Q1 '20: 106.5M Q2 '20: 107.1M Q3 '20: 117.6M Q1 '21: 143.4M Q2 '21: 144.5M Q3 '21: 145.8M Q1 '22: 149.2M Q2 '22: 149.6M Q3 '22: 174.9M Q1 '23: 189M Q2 '23: 204.8M Q3 '23: 244.9M Q1 '24: 245.4M Q2 '24: 310.8M Q3 '24: 361.5M Q1 '25: 362.1M Q2 '25: 363.6M Q3 '25: 363.4M Q1 '26: 400.2M Q2 '26: 437.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.90 -0.60 -0.30 0.00 0.30 0.60 0.90 Q3 '21: -0.47 Q4 '21: -0.61 Q1 '22: -0.62 Q2 '22: -0.65 Q3 '22: -0.62 Q4 '22: -0.62 Q1 '23: -0.63 Q2 '23: -0.69 Q3 '23: -0.77 Q4 '23: -0.80 Q1 '24: -0.83 Q2 '24: -0.78 Q3 '24: -0.75 Q4 '24: -0.64 Q1 '25: -0.51 Q2 '25: -0.33 Q3 '25: -0.19 Q4 '25: -0.14 Q1 '26: -0.07 Q2 '26: -0.15 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.